Comparison
Ipamorelin vs. Bremelanotide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Research other
CAS no.
170851-70-4
189691-06-3
Molecular weight
711.86 g/mol
1025.18 g/mol
Half-life
2 h
2.7 h
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHMechanism of action
Ipamorelin
Ipamorelin is a selective agonist at the GH secretagogue receptor (GHSR-1a). Compared to GHRP-2 and GHRP-6 its selectivity for the growth-hormone axis is higher; ACTH, cortisol and prolactin are not significantly stimulated in clinical studies. This selectivity was the main reason for its development over older GHRPs.
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
5
of which in humans
3
5
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
2